Filana Therapeutics Will Attend 2026 Maxim Growth Summit
The biotech firm will join investor meetings at the Hard Rock Hotel NYC from October 12-14, 2026.
Updated on Oct. 9, 2026 in Biotech
Filana Therapeutics is scheduled to participate in the 2026 Maxim Growth Summit, which will take place in New York City from October 12-14, 2026. The company management team will engage in a series of one-on-one meetings at the Hard Rock Hotel NYC.
Why it matters
The summit provides a platform for the biotechnology firm to present its development efforts for therapies targeting Tuberous Sclerosis Complex-related epilepsy. This appearance allows management to connect directly with investors during the multi-day industry conference.
The 2026 Maxim Growth Summit spans three days and features a format centered on one-on-one meetings between company representatives and industry participants. Filana Therapeutics is currently based in Austin, Texas.
The players
Filana Therapeutics
This biotechnology company focuses on the development of medical therapies for Tuberous Sclerosis Complex-related epilepsy.
The details
Filana Therapeutics will send its management team to the event to focus on its pipeline of therapies designed to treat epilepsy associated with Tuberous Sclerosis Complex. The event serves as a specialized venue for direct engagement between emerging biotech entities and the investment community.
Timeline
The 2026 Maxim Growth Summit is scheduled for October 12-14, 2026.
The Tech Race
The participation of Filana Therapeutics follows a pattern of emerging biotech firms utilizing professional growth summits to gain investor visibility. These gatherings represent a critical step in the industry-wide push to secure funding for specialized orphan disease research.
Investors and industry analysts interested in the biotech sector should monitor upcoming disclosures from the event for potential shifts in the company's development pipeline. For the broader public, the summit highlights ongoing corporate efforts to advance treatments for complex neurological conditions.
The takeaway
Participation in professional summits is a key indicator of a biotechnology firm's growth strategy and its engagement with the capital markets. Readers tracking the medical sector should watch for how these investor interactions influence future research funding for neurological therapies.
Further reading
For broader trends in medical innovation, visit our Biotech section.
More information
Review the full schedule and venue details on the Maxim Growth Summit information page.
